ProShare Advisors
MRVI icon

ProShare Advisors’s Maravai LifeSciences MRVI Stock Holding History

ProShare Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$122K Sell
19,611
-2,782
-12% -$12K ﹤0.01% 1748
2026
Q1 		$63.4K Sell
22,393
-3,985
-15% -$13.5K ﹤0.01% 1762
2025
Q4 		$85.7K Buy
26,378
+2,536
+11% +$8.54K ﹤0.01% 1895
2025
Q3 		$68.4K Sell
23,842
-6,564
-22% -$16.8K ﹤0.01% 1897
2025
Q2 		$73.3K Sell
30,406
-17,568
-37% -$36.9K ﹤0.01% 1933
2025
Q1 		$106K Sell
47,974
-7,514
-14% -$29.7K ﹤0.01% 1820
2024
Q4 		$302K Buy
55,488
+26,251
+90% +$169K ﹤0.01% 1624
2024
Q3 		$243K Buy
+29,237
New +$253K ﹤0.01% 1609
2023
Q1 		– Sell
-12,538
Closed -$179K – 1865
2022
Q4 		$179K Sell
12,538
-266
-2% -$4.19K ﹤0.01% 1521
2022
Q3 		$327K Buy
12,804
+785
+7% +$19.7K ﹤0.01% 1097
2022
Q2 		$342K Sell
12,019
-4,075
-25% -$129K ﹤0.01% 1138
2022
Q1 		$568K Sell
16,094
-5,159
-24% -$173K ﹤0.01% 1200
2021
Q4 		$891K Buy
+21,253
New +$861K ﹤0.01% 1096

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

ProShare Advisors's MRVI Position: Q2 2026 in Review

ProShare Advisors reduced its Maravai LifeSciences (MRVI) stake by 12% in Q2 2026, selling an estimated $12K and leaving 19,611 shares worth $122K. The position accounts for ﹤0.01% of the portfolio, ranked #1748.

ProShare Advisors first reported a position in MRVI in Q4 2021 and has held it in 13 quarters since. The position peaked at $891K in Q4 2021. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • ProShare Advisors held 19,611 shares of Maravai LifeSciences worth $122K as of Q2 2026.
  • ProShare Advisors sold 2,782 Maravai LifeSciences shares in Q2 2026, an estimated $12K.
  • Maravai LifeSciences made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1748 holding.
  • ProShare Advisors first reported a position in Maravai LifeSciences in Q4 2021 and has held it in 13 quarters since.
  • ProShare Advisors's Maravai LifeSciences position peaked at $891K in Q4 2021.
  • 178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.